此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Clinical Study of HH-1270 in Healthy Chinese Subjects

2026年11月17日 更新者:Huahui Health

A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HH-1270 Tablets in Healthy Chinese Participants

This study is a single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial to evaluate the safety and PK profile in healthy Chinese subjects.

研究概览

详细说明

SAD consists of 6 prespecified dose levels. Participants are enrolled in cohorts according to the dose-escalation principle and randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of single-dose HH-1270. One dose cohort in the SAD phase will be selected for a food-effect exploration.

MAD consists of 4 prespecified dose levels. Each participant receives once-daily dosing under fasting conditions for 7 consecutive days and is randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of multiple-dose HH-1270.

研究类型

介入性

注册 (估计的)

88

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100191
        • 招聘中
        • Peking University Third Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 55年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Healthy Chinese adults aged 18 to 55 years (inclusive), both male and female.
  • Weight: male ≥50.0 kg, female ≥45.0 kg, and body mass index (BMI) 18.0 to 28.0 kg/m² (inclusive; BMI = weight/height²).
  • Results of vital signs, physical examination, laboratory tests, and 12-lead electrocardiogram (ECG) at screening are normal or abnormal without clinical significance.
  • Participants must agree to take adequate and effective contraceptive measures.
  • Participants understand and comply with the study procedures, voluntarily participate, and sign the informed consent form (ICF).

Exclusion Criteria:

  • Individuals with severe systemic diseases, infectious diseases, or mental disorders.
  • Clinically significant electrocardiogram (ECG) abnormalities.
  • History of clinically significant drug allergy or atopic allergic diseases.
  • Comorbid conditions that may affect drug absorption, distribution, metabolism, excretion, and interpretation of safety data, or that may reduce compliance, including but not limited to any of the following.
  • Positive results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or Treponema pallidum antibody (TPAb).
  • History of drug abuse or alcoholism within 12 months before screening, or evidence of alcohol abuse or excessive drinking confirmed by an alcohol breath test at screening.
  • Frequent use of tobacco or nicotine products (e.g., patches, gum, etc.) or any other smoking products within 30 days before screening.
  • Blood donation ≥400 mL within 3 months before screening.
  • Participation in another interventional clinical trial within 3 months before screening.
  • Use of any prescription medication within 4 weeks or 5 half-lives (whichever is longer) before screening.
  • Use of over-the-counter drugs, health supplements, herbal medicines, or traditional Chinese medicines, or use of medications that affect drug metabolism, within 2 weeks before screening.
  • Known or suspected history of allergy to any component of HH-1270 tablets or their excipients.
  • Inability to accept standardized diet management at the study center.
  • Participants who are breastfeeding or have a positive pregnancy test before the first dose.
  • Participants deemed unsuitable for participation in the study by the investigator.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:HH-1270 group

SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days

SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days

安慰剂比较:Placebo group

SAD groups will be received HH-1270 placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days

SAD groups will be received placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of adverse events (AEs) and serious adverse events (SAEs)
大体时间:up to 15/21 days in SAD/MAD

Number of subjects with adverse events (AEs) and serious adverse events (SAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v6.0.

up to 15/21 days in SAD/MAD
Clinically significant abnormalities
大体时间:up to 14/21 days in SAD/MAD

Number of subjects with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v6.0.

up to 14/21 days in SAD/MAD

次要结果测量

结果测量
措施说明
大体时间
Area Under the Plasma Concentration Versus Time Curve (AUC)
大体时间:up to 8/14 days in SAD/MAD

AUC of HH-1270 in plasma

up to 8/14 days in SAD/MAD
Maximum Plasma Concentration (Cmax)
大体时间:up to 8/14 days in SAD/MAD

Cmax of HH-1270 in plasma

up to 8/14 days in SAD/MAD
Time to Reach Maximum Plasma Concentration (Tmax)
大体时间:up to 8/14 days in SAD/MAD

Tmax of HH-1270 in plasma

up to 8/14 days in SAD/MAD
Apparent Terminal Elimination Half-life (T1/2)
大体时间:up to 8/14 days in SAD/MAD

T1/2 of HH-1270 in plasma

up to 8/14 days in SAD/MAD
Apparent Plasma Clearance (CL/F)
大体时间:up to 8/14 days in SAD/MAD

CL/F of HH-1270 in plasma

up to 8/14 days in SAD/MAD
Apparent volume of distribution(Vd/F)
大体时间:up to 8/14 days in SAD/MAD

Vd/F of HH-1270 in plasma

up to 8/14 days in SAD/MAD
To evaluate the TBA level
大体时间:up to 15/21 days in SAD/MAD

TBA level for each collection point

up to 15/21 days in SAD/MAD
To evaluate the CP-1 level
大体时间:up to 15/21 days in SAD/MAD

CP-1 level for each collection point

up to 15/21 days in SAD/MAD

其他结果措施

结果测量
措施说明
大体时间
To evaluate QTc change
大体时间:up to 8 days in SAD

QTc values in each collection point

up to 8 days in SAD

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月19日

初级完成 (估计的)

2027年2月5日

研究完成 (估计的)

2027年7月6日

研究注册日期

首次提交

2026年10月9日

首先提交符合 QC 标准的

2026年10月9日

首次发布 (实际的)

2026年10月15日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月17日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • HH1270-101

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅